Table 2.
Details of the key targets
| Key targets | Betweenness centrality | Closeness centrality | Degree |
|---|---|---|---|
| TNF | 0.07224798 | 0.65882353 | 33 |
| IL-6 | 0.06024239 | 0.65116279 | 33 |
| VEGF | 0.09232003 | 0.66666667 | 31 |
| AKT1 | 0.1051178 | 0.64367816 | 28 |
| TP53 | 0.08365778 | 0.62921348 | 26 |
| MMP9 | 0.07389262 | 0.62222222 | 26 |
| IL-1β | 0.01989997 | 0.58947368 | 25 |
| CASP3 | 0.0375621 | 0.57731959 | 21 |
| RELA | 0.03861559 | 0.57142857 | 21 |
| EGF | 0.03017289 | 0.56565657 | 20 |
| MYC | 0.05219103 | 0.56 | 17 |
| PTGS2 | 0.0320954 | 0.54368932 | 17 |
| MAPK1 | 0.0283965 | 0.54368932 | 16 |
| MMP2 | 0.0200976 | 0.53846154 | 14 |
Notes: TNF: tumor necrosis factor; IL-6: interleukin-6; VEGF: vascular endothelial growth factor; AKT1: AKT serine/threonine kinase 1; TP53: tumor protein p53; MMP9: matrix metalloproteinase 9; IL-1β: interleukin-1 beta; CASP3: caspase 3; RELA: RELA proto-oncogene; EGF: epidermal growth factor; MYC: MYC proto-oncogene, PTGS2: prostaglandin-endoperoxide synthase 2; MAPK1: mitogen-activated protein kinase 1; MMP2: matrix metalloproteinase 2.